Hosted on MSN3h
The New Gold Rush in Rare Disease Treatments and Merck KGaA’s Acquisition of SpringWorks TherapeuticsFor many years, the pharmaceutical business concentrated mostly on blockbuster medications, which are cures for common ...
Merck KGaA’s U.S. pharma arm has recruited actor Selma Blair for a collaboration around multiple sclerosis treatment Mavenclad. | No cruel intentions here: Merck KGaA’s U.S. pharma arm has recruited ...
GlobalData on MSN1d
New CEOs to join Merck KGaA’s executive boardJean-Charles Wirth and Danny Bar-Zohar are set to assume the life science and healthcare CEO roles respectively.
In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price ...
The German pharmaceutical-and-chemicals company on Tuesday said it appointed Jean-Charles Wirth as new chief executive of life science. Wirth succeeds Matthias Heinzel, who decided to not renew his ...
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...
The latest example of this trend is Merck KGaA’s impending all-cash acquisition of SpringWorks Therapeutics, valued around ...
RxTechExam and the Pennsylvania Pharmacists Association announced a strategic partnership. Roche’s $8 billion InterMune acquisition has been handed to a specialty pharmaceutical company, Cayman ...
Wedbush raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $81 from $77 and keeps an Outperform rating on the shares ...
The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback